Two Sigma Advisers’s Acceleron Pharma XLRN Stock Holding History

Two Sigma Advisers’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-90,100	Closed	-$11.5M	–	2780
2020 Q4	$11.5M	Sell	90,100 -57,300	-39%	-$6.72M	0.03%	521
2020 Q3	$16.6M	Buy	147,400 +23,700	+19%	+$2.36M	0.05%	366
2020 Q2	$11.8M	Buy	123,700 +76,700	+163%	+$7.39M	0.03%	495
2020 Q1	$4.22M	Buy	47,000 +38,700	+466%	+$3.01M	0.02%	772
2019 Q4	$440K	Sell	8,300 -41,600	-83%	-$1.9M	﹤0.01%	1921
2019 Q3	$1.97M	Sell	49,900 -17,400	-26%	-$755K	﹤0.01%	1117
2019 Q2	$2.77M	Sell	67,300 -3,000	-4%	-$124K	0.01%	1070
2019 Q1	$3.27M	Buy	+70,300	New	+$3.09M	0.01%	996

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Advisers's XLRN Position: Q1 2021 in Review

Two Sigma Advisers sold out of Acceleron Pharma (XLRN) in Q1 2021, closing a stake of 90,100 shares — an estimated $11.5M sold.

Two Sigma Advisers first reported a position in XLRN in Q1 2019 and held it in 8 quarters. The position peaked at $16.6M in Q3 2020. 256 funds tracked by Wall St. Rank hold XLRN as of Q1 2021.

Two Sigma Advisers reported no remaining Acceleron Pharma position as of Q1 2021 after selling out during the quarter.
Two Sigma Advisers sold 90,100 Acceleron Pharma shares in Q1 2021, an estimated $11.5M.
Two Sigma Advisers first reported a position in Acceleron Pharma in Q1 2019 and held it in 8 quarters.
Two Sigma Advisers's Acceleron Pharma position peaked at $16.6M in Q3 2020.
256 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2021.

Based on Two Sigma Advisers's 13F filing for Q1 2021, filed 17 May 2021.